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Objectives: Discrete-Event-Simulation (DES) is a commonly used modeling 
tool to analyze the comparative effectiveness of alternative health technologies 
and to optimize resource allocation in health care settings. DES models are often 
rather complex and visualization is very important to improve transparency and 
acceptability. This study aims to illustrate and contrast alternative visualization 
techniques on a decision-analytic model for breast cancer. MethOds: DES visu-
alization methods and their applications in health care, engineering, and opera-
tions research were sought from a wide variety of sources, including literature 
databases (e.g., PubMed) and webpages of simulation conference (e.g., Winter 
Simulation Conference), academic societies etc. Based on this review, alternative 
visualization techniques for the conceptual model were selected, applied on a real 
world modeling example and compared. Results: In health care, the recently 
published ISPOR-SMDM Modeling Good Research Practice guidelines recommend 
flow diagrams or state charts to represent the key elements of a model, including 
the possible pathways, and the presence of queues and decision points. For flow 
charts, we found an international standard (ISO 5807). The application of standards 
like this could support harmonization of process-oriented models. In general, flow 
charts may lack the information of health states and transitions between health 
states that are relevant for clinicians to review the model. The semantic for state 
charts invented by Harel provides a further development of the bubble diagrams 
of State-Transition (Markov) Models (e.g. one state containing other states, one 
state detects changes in another). In state charts, health states could explicitly 
be named but treatment processes and resources use are less explicit. For DES 
software implementation, state charts seem to be less intuitive. For both methods, 
the application of visualization standards and guidelines was not always straight 
forward for our breast cancer model. cOnclusiOns: In the case example there 
was no superior visualization technique.
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Objectives: Most cancer care models are based on observed clinical events such 
as recurrence-free and overall survival. Times at which events are recorded depend 
not only on effectiveness of treatment, but also on timing of examinations and 
types of tests performed. Should these change, observation times would change 
as well. Construct a microsimulation model that describes the cancer disease 
process using a description of underlying tumor growth as well as its interaction 
with diagnostics, treatments and surveillance. The aim is to arrive at a frame-
work that allows for exploration of the impact of simultaneously altering two 
or more aspects of the care process. MethOds: The framework consists of two 
components; the disease model and the clinical management module. The disease 
model consists of atumor level, describing the growth and metastasis of the tumor, 
and a patient level, describing clinical observed states, such as recurrence and 
death, either from the disease or other causes. The clinical management module 
consists of the care patients receive, i.e. the diagnostic process, treatment and 
surveillance. This module interacts with the disease process, influencing the rate 
of transitioning between tumor growth states at the tumor level, and the rate of 
detecting a recurrence at the patient level. Results: A simulation study was 
performed to examine the feasibility of applying the framework to melanoma 
progression. Results demonstrated stage specific recurrence rates similar to those 
found in literature. cOnclusiOns: The proposed microsimulation model frame-
work allows for generating individual patient histories by simulating underlying 
tumor growth in interaction with clinical management. Our modeling approach 
allows for the exploration of the potential of drugs intervening in different parts 
of the tumor growth pathway. In addition, the approach allows for the evaluation 
of changing diagnostic patterns.
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Objectives: Economic evaluations typically include all costs relevant to a disease, 
not only drug-related costs. This is particularly relevant to oncology modelling, as 
costs are assigned to each health state in the model, and, therefore, extending sur-
vival also increases costs. Because patients often incur higher health care costs in 
the post-progressed state of disease where costs of disease management are high, 
extending survival and increasing a patient’s time in the post-progressed stage 
can be particularly costly. Empirical analyses of the implications of such methods 
have not yet been extensively investigated by assessing different scenarios such as 
baseline severity and prognosis. The objective of this research was to investigate 
the methodology used in oncology modelling, and to determine the effect that this 
has on predicted cost-effectiveness. MethOds: We developed a flexible three-state 
Zidovudine + Lamivudine combination therapy vs Zidovudine monotherapy, to 
treat HIV infection. Based on probabilistic simulations, cumulative incremental 
net monetary benefits (CINMB) at a CE threshold of £20,000/QALY and probabili-
ties of being cost-effective at various time-horizons (1-20 years) were estimated. 
Further, for each time-horizon, a CINMB frequency distribution was plotted and 
summary statistics were estimated. Results: For the combination therapy, while 
the outcome uncertainty increased over time, the decision uncertainty decreased. 
95% confidence interval for expected CINMB was narrowest at year 1 (-1,771£ to 
-1,755£) and widest at year 7 (2,101£ to 2,209£); simultaneously the probability of 
being cost effective increased from 5% to 80% during this time. Outcome uncer-
tainty, measured as the standard deviation of CINMB values stabilized after 5 
years while probability of the combination therapy being cost effective continued 
to increase, indicating that decision uncertainty does not vary in tandem with 
outcome uncertainty. cOnclusiOns: The above analysis shows that higher out-
come uncertainty does not necessarily lead to higher decision uncertainty. CINMB 
could be a useful tool to observe the relationships between outcome uncertainty, 
decision uncertainty and time.
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Objectives: To describe the practical approach implemented to construct a 
global cost-effectiveness model for T2DM therapies following a framework pro-
posed for the development of reference models to inform public funding deci-
sions. MethOds: 1) A systematic review of published models was conducted to 
conceptualise the model in terms of natural history and relevant effects to include. 
2) Clinical and health economic experts were selected to provide feedback during 
the model conceptualisation (to identify the appropriate modelling technique), the 
model implementation and the assessment of the results. 3) The model was built 
and populated based on the systematic identification of best available data, a net-
work meta-analyses, a review of previous T2DM submissions to health authorities 
and other published information. The model incorporated several structures for 
uncertain areas, such as: treatment patterns; type and timing of adverse events; 
their impact in the occurrence of long-term complications; and the impact of weight 
changes on relevant endpoints. 4) The model was then validated based on out-
puts’ accuracy, feedback from country affiliates and consistency with the CORE 
model results. 5) The critical feedback received by HTA bodies has also been used 
to refine the model and improve its credibility accordingly. Results: Experts’ input 
proved invaluable at each developmental stage. One challenge related to the com-
parability with other published T2DM models, which were not fully transparent 
regarding assumptions. This framework resulted in a flexible model, accurate and 
stable, and easily adaptable to different health care systems. Country adaptations 
have contributed to the identification of aspects that require relevant structural 
changes and their rationale. cOnclusiOns: The followed framework enhanced 
the transparency of the model and the accuracy of the results. Using a reference 
model across different countries, with adaptations made in consistency with this 
model, should help ensure consistent and comparable evaluations of the model 
across different countries.
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Objectives: Payers have a perception that orphan products are extremely 
expensive. The current health technology assessment (HTA) systems might be 
too restrictive for orphan drugs, therefore potentially denying patients access to 
life-saving medicines. While price is important, it should be considered in relation 
to a broader range of product attributes, such as unmet need and disease severity 
that are not considered in cost-effectiveness analysis used by many HTA agencies. 
To overcome these challenges multi-criteria decision analysis (MCDA) has been 
proposed as an alternative to evaluate technologies. The aim of this study was to 
identify criteria reported in the literature, and to assess their impact on the total 
“score” for each product in relation to price. MethOds: A systematic literature 
review was conducted to identify the most frequently cited attributes in MCDA. 
From the leading attributes identified, we reviewed and plotted the relationship 
between single attributes and the average annual treatment costs for several drugs 
used in the treatment of endocrine-related rare diseases. Annual treatment cost 
was based on UK prices for the average daily dose per patient. Results: The 
three most frequently mentioned attributes were ‘disease severity’, ‘treatment 
impact on condition’, and ‘level of research undertaken to support use of the prod-
uct’. Disease severity was not shown to influence product price. Similarly, orphan 
drugs are not necessarily more expensive than products without orphan drug 
status. There is little discernible relationship between treatment ‘convenience’ 
and average annual treatment cost. A trend was observed between the market size 
and the average annual treatment cost. cOnclusiOns: If society is concerned 
about equity and equal access to medicines for all patients, MCDA may offer a 
viable alternative to inform in reimbursement decisions for orphan drugs. The 
analysis can be used to inform investigations on the application of MCDAs in 
rare diseases.
